Taxol, Paclitaxel Newswire

Taxol, Paclitaxel Newswire

Comprehensive Real-Time News Feed for Taxol, Paclitaxel (generic).

Results 1 - 17 of 17 in Taxol, Paclitaxel (generic)

  1. Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR...Read the original story

    Monday | Customer Interaction Solutions

    Hutchison China MediTech Limited today announces that data from the ongoing Phase I/II clinical trial of fruquintinib in combination with paclitaxel in second-line patients with advanced gastric cancer will be presented at the 2017 Gastrointestinal Cancers Symposium sponsored by the American Society of Clinical Oncology , being held in San Francisco, California from January 19 to 21, 2017. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors .

    Comment?

  2. The key to determining the right treatment for breast cancerRead the original story w/Photo

    Nov 23, 2016 | PhysOrg Weblog

    The Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital has received the highest accolade for its research work in the field of breast cancer: top medical journal The Lancet commissioned Michael Gnant, Head of the Department of Surgery, Head of the Breast Health Center and Deputy Head of the CCC, and Nadia Harbeck, Head of the Breast Center at Ludwig-Maximilians-University, Munich, to write a paper reviewing the very latest standards in the treatment of breast cancer. The main finding: For breast cancer as well, it's all about precision medicine, the most significant trend in 21st century medicine.

    Comment?

  3. Biomarker could help guide cancer therapy, avoid drug resistanceRead the original story w/Photo

    Nov 22, 2016 | Science Blog

    MIT biologists have identified a new biomarker that can reveal whether patients with a particularly aggressive type of breast cancer will be helped by paclitaxel , one of the drugs most commonly used to treat this cancer. The findings could offer doctors a new way to choose drugs for this type of breast cancer, known as triple-negative because it lacks the three most common breast cancer markers: estrogen receptor, progesterone receptor, and Her2 protein.

    Comment?

  4. Biologists link levels of Mena protein to breast cancer cells' sensitivity to chemotherapyRead the original story w/Photo

    Nov 22, 2016 | PhysOrg Weblog

    This image shows triple-negative breast cancer cells with high levels of "Mena invasive" protein and treated with Paclitaxel. The cell cytoskeleton is shown in blue, the dynamic microtubules are shown in green, and the stable microtubules are shown in red.

    Comment?

  5. Diazon Pharmaceuticals ' Anti-Cancer Agent DZ-2384 Mechanism For...Read the original story

    Nov 16, 2016 | BioSpace

    Diazon Pharmaceuticals ' Anti-Cancer Agent DZ-2384 Mechanism For High Activity And Low Neurotoxicity Published By McGill University Researchers In Science Translational Medicine /PRNewswire/ -- Diazon Pharmaceuticals Inc. today announced the publication of a preclinical oncology study identifying the novel mechanism of action of its new synthetic diazonamide compound, DZ-2384, in Science Translational Medicine . The results show that a distinct mode of binding to a classic therapeutic site in tubulin translates into superior anti-tumor activity and safety, including lack of neurotoxicity, with pre-clinical proof of concept in a wide range of cancers including triple-negative breast cancer and pancreatic cancer.

    Comment?

  6. Diazon Pharmaceuticalsa anti-cancer agent DZ-2384 mechanism for high...Read the original story w/Photo

    Nov 16, 2016 | Freshnews

    Diazon Pharmaceuticals Inc. today announced the publication of a preclinical oncology study identifying the novel mechanism of action of its new synthetic diazonamide compound, DZ-2384, in Science Translational Medicine . The results show that a distinct mode of binding to a classic therapeutic site in tubulin translates into superior anti-tumor activity and safety, including lack of neurotoxicity, with pre-clinical proof of concept in a wide range of cancers including triple-negative breast cancer and pancreatic cancer.

    Comment?

  7. Paclitaxel induces calcium oscillations via an inositol...Read the original story

    Oct 29, 2016 | CiteULike

    Proceedings of the National Academy of Sciences , Vol. 103, No. 48. , pp. 18356-18361, doi:10.1073/pnas.0607240103 To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  8. Global Ovarian Cancer Drugs Market 2016: Industry Review, Insights, Demand and Analysis to 2021Read the original story w/Photo

    Oct 21, 2016 | SBWire

    Ovarian cancer is cancer that affects the ovaries. According to the WHO, an estimated 2,38,700 women were diagnosed with ovarian cancer in 2012.

    Comment?

  9. Madison Startup Advances Three-in-One Cancer Drug Rooted at UWRead the original story

    Oct 20, 2016 | Newswise

    MADISON, Wis. - Co-D Therapeutics, a University of Wisconsin-Madison spinoff, is developing a three-drug cocktail to battle a wide range of cancers.

    Comment?

  10. Animal study shows Cellectar's CLR 1602 may deliver up to 30x the...Read the original story w/Photo

    Jun 15, 2016 | Seeking Alpha

    Nano cap Cellectar Biosciences heads north on a 2.5x surge in volume in response to its announcement of preliminary results from an in vivo tumor-targeting study in mice that showed product candidate CLR 1602, a phospholipid drug conjugate, could be more than 30x more tumor selective than free paclitaxel. The data will be presented at the 35th National Medicinal Chemistry Symposium in Chicago at the end of the month.

    Comment?

  11. Oasmia reviewing proposals from firms interested in API solubility enchancement techRead the original story w/Photo

    May 31, 2016 | Drug Researcher

    The Swedish firm said it has begun assessing proposals from companies interested in the XR17 technology - which is used to solubilize insoluble active pharmaceutical ingredients - but did not respond to a request for more information. Oasmia also said it planned to ramp up efforts to find marketing and distribution partners for own brand products developed using the technology adding that it has already held talks with " multiple potential partners.

    Comment?

  12. Oasmia reviewing proposals from firms interested in API solubility enchancement techRead the original story w/Photo

    May 31, 2016 | In-PharmaTechnologist.com

    The Swedish firm said it has begun assessing proposals from companies interested in the XR17 technology - which is used to solubilize insoluble active pharmaceutical ingredients - but did not respond to a request for more information. Oasmia also said it planned to ramp up efforts to find marketing and distribution partners for own brand products developed using the technology adding that it has already held talks with " multiple potential partners.

    Comment?

  13. New anti-diabetic ayurvedic med can hit markets soonRead the original story w/Photo

    Apr 29, 2016 | The Times of India

    NEW DELHI: A new anti-diabetic medicine made from five ayurvedic medicinal plants is likely to hit the market very soon. The Central Council of Research in Ayurvedic Sciences has developed a new drug formulation AYUSH-82, which has proven clinically efficient in treatment of diabetes, AYUSH minister Shripad Yesso Naik said.

    Comment?

  14. Two-Step Delivery Method Ups Cancer Drug's Concentration In TumorsRead the original story

    Jan 20, 2016 | Chemical & Engineering News

    Researchers report that cancer therapies involving drugs such as Taxol might be made more effective if clinicians did the two-step when administering them.

    Comment?

  15. Split decision: a new approach to taxol precursorsRead the original story w/Photo

    Nov 8, 2010 | Examiner.com

    For many years, the anticancer drug Taxol and its derivatives have been successfully used in the treatment of human breast, lung, and ovarian tumors. Taxol, first isolated from the bark of the Pacific yew tree, belongs to a lipid class called terpenoids or isoprenoids, the largest group of natural compounds.

    Comment?

  16. Two-Step Delivery Method Ups Cancer Drug's Concentration In TumorsRead the original story

    Jan 20, 2016 | Chemical and Engineering News

    Researchers report that cancer therapies involving drugs such as Taxol might be made more effective if clinicians did the two-step when administering them.

    Comment?

  17. Split decision: a new approach to taxol precursorsRead the original story w/Photo

    Nov 8, 2010 | Examiner.com

    For many years, the anticancer drug Taxol and its derivatives have been successfully used in the treatment of human breast, lung, and ovarian tumors. Taxol, first isolated from the bark of the Pacific yew tree, belongs to a lipid class called terpenoids or isoprenoids, the largest group of natural compounds.

    Comment?